Prescription drugs can be life-changing, but for some, the price tag hits like a punch to the gut. It’s one of the reason that Donald Trump started the week by signing a sweeping executive order to slash drug prices this week. (On a side note: The FDA is forecasted to approve 43 drugs and there’s a 25% chance that Trump will get rid of Medicare drug negotiation this year, according to the prediction market Kalshi.)
From rare disease treatments to cutting-edge cancer therapies, these are the medications that come with a jaw-dropping bill.
Hemgenix ($3.5 million per dose)
Used to treat hemophilia B, this single-dose gene therapy aims to reduce or eliminate the need for ongoing blood clotting factor infusions, offering patients a shot at a more normal life.
Skysona ($3 million per course)
This therapy targets cerebral adrenoleukodystrophy (CALD), a rare, devastating neurological disease. It’s a one-time infusion designed to slow disease progression, but it comes with a price tag that reflects its life-changing impact.
Zolgensma ($2.1 million per dose)
One of the most expensive drugs in the world, Zolgensma treats spinal muscular atrophy (SMA) in children under two. It’s a one-time gene therapy designed to replace a defective gene – a miracle cure, with a matching price.
Myalept ($890,000 per year)
Developed for patients with generalized lipodystrophy, a rare disorder that prevents the body from storing fat, Myalept helps regulate blood sugar and fat levels – a literal lifesaver for those who need it.
Luxturna ($850,000 per dose)
This groundbreaking gene therapy can restore sight to people with a rare form of inherited retinal disease. It’s a one-time injection directly into the eye, designed to restore vision for life.
Kimmtrak ($730,000 per year)
A treatment for a rare form of eye cancer called uveal melanoma, Kimmtrak harnesses the power of the immune system to target and destroy cancer cells.
Brineura ($730,000 per year)
Used to treat a rare pediatric brain disorder called Batten disease, Brineura slows the disease’s progression, helping children maintain mobility for longer.
Folotyn ($570,000 per year)
This chemotherapy drug is used to treat peripheral T-cell lymphoma, a rare and aggressive form of blood cancer. It’s a heavy hitter with a matching price.
Blincyto ($450,000 per year)
Designed for certain types of acute lymphoblastic leukemia, Blincyto is a targeted immunotherapy that activates the body’s own T-cells to fight off cancer.
Actimmune ($430,000 per year)
Used to boost the immune system in patients with chronic granulomatous disease and severe malignant osteopetrosis, Actimmune helps reduce infections and improve survival rates.
